Stock DAWN DAY ONE BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
16.48 USD +10.46% Intraday chart for Day One Biopharmaceuticals, Inc. +7.15% +12.88%
Apr. 29 North American Morning Briefing : Investors Brace -2- DJ
Apr. 24 Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Investors Brace -2-
DJ
Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating
MT
Transcript : Day One Biopharmaceuticals, Inc. - Special Call
Day One Biopharmaceuticals : Corporate Presentation - April 2024
PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
AQ
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
CI
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment
MT
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
DJ
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating
MT
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing
MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating
MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating
MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating
MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
GL
Day One Biopharmaceuticals, Inc. Announces Executive Changes
CI
Day One Announces Two New Appointments to Board of Directors
GL
Day One Biopharmaceuticals, Inc. Announces Board Appointments
CI
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DAWN Stock
  4. News Day One Biopharmaceuticals, Inc.